- Report
- February 2024
- 174 Pages
Global
From €3372EUR$3,825USD£2,927GBP
€3968EUR$4,500USD£3,444GBP
- Report
- October 2023
- 172 Pages
Global
From €3372EUR$3,825USD£2,927GBP
€3968EUR$4,500USD£3,444GBP
- Report
- November 2023
- 188 Pages
Global
From €3372EUR$3,825USD£2,927GBP
€3968EUR$4,500USD£3,444GBP
- Report
- February 2024
- 110 Pages
Global
From €4188EUR$4,750USD£3,635GBP
- Report
- February 2024
- 114 Pages
Global
From €4188EUR$4,750USD£3,635GBP
- Report
- February 2024
- 110 Pages
Global
From €4188EUR$4,750USD£3,635GBP
- Report
- February 2024
- 179 Pages
Global
From €4188EUR$4,750USD£3,635GBP
- Report
- May 2024
- 200 Pages
Global
From €3659EUR$4,150USD£3,176GBP
- Report
- April 2023
- 150 Pages
Global
From €2865EUR$3,250USD£2,487GBP
€4276EUR$4,850USD£3,711GBP
- Report
- August 2024
- 111 Pages
From €3042EUR$3,450USD£2,640GBP
- Report
- June 2024
- 74 Pages
From €3042EUR$3,450USD£2,640GBP
- Report
- June 2024
- 80 Pages
Africa, Middle East
From €3042EUR$3,450USD£2,640GBP
- Report
- June 2024
- 90 Pages
Asia Pacific
From €3042EUR$3,450USD£2,640GBP
- Report
- June 2024
- 93 Pages
Europe
From €3042EUR$3,450USD£2,640GBP
- Report
- June 2024
- 76 Pages
North America
From €3042EUR$3,450USD£2,640GBP
- Report
- January 2024
- 210 Pages
Global
From €3923EUR$4,450USD£3,405GBP
- Report
- November 2023
- 176 Pages
Global
From €3923EUR$4,450USD£3,405GBP
- Report
- June 2023
- 194 Pages
Global
From €3923EUR$4,450USD£3,405GBP
- Report
- April 2024
- 114 Pages
Global
From €2786EUR$3,160USD£2,418GBP
€3483EUR$3,950USD£3,023GBP
- Report
- July 2023
- 119 Pages
Global
From €3968EUR$4,500USD£3,444GBP

Single Use Bioreactors (SUBs) are bioreactors that are designed for a single use and then disposed of. They are used in biotechnology for the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. SUBs are typically made of plastic and are pre-sterilized, eliminating the need for cleaning and sterilization between batches. This makes them ideal for rapid scale-up and production of biopharmaceuticals. SUBs also offer advantages such as reduced risk of contamination, improved process control, and reduced capital costs.
The SUB market is growing rapidly due to the increasing demand for biopharmaceuticals and the need for rapid scale-up and production. SUBs are becoming increasingly popular in the biotechnology industry due to their cost-effectiveness and convenience.
Some companies in the SUB market include Sartorius, Thermo Fisher Scientific, Merck KGaA, GE Healthcare, and Pall Corporation. Show Less Read more